Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 2/2013

01-04-2013

Effect of Lipoxin A4 on Myocardial Ischemia Reperfusion Injury Following Cardiac Arrest in a Rabbit Model

Published in: Inflammation | Issue 2/2013

Login to get access

Abstract

In the present study, we investigated the effect of lipoxin A4 on myocardial ischemia–reperfusion injury (IRI) following cardiac arrest (CA) in a rabbit model. Lipoxin A4 is a metabolite of arachidonic acid in the eicosanoid, it is called “brake signal” for its anti-inflammatory activity. Some inflammatory factors (IL-1β, IL-6, TNF-α, and IL-10), NF-κB p65, infarct ratios, apoptotic index, cardiac troponin I (cTnI), hemodynamic and myocardial structures were measured or observed in different groups. Lipoxin A4 inhibits the expression of IL-1β, IL-6, and TNF-α, the values of the infarct ratios, apoptotic index, the level of serum cTnI and NF-κB p65. Meanwhile, it improves the expression of IL-10, hemodynamic, myocardial structure, and function. These indicate that lipoxin A4 mitigates postresuscitation myocardial IRI in which anti-inflammation and suppression of NF-κB activation may play an important role.
Literature
1.
de Vreede-Swagemakers, J.J.M., A.P.M. Gorgels, W.I. Dubois-Arbouw, J.W. van Ree, M.J.A.P. Daemen, L.G.E. Houben, and H.J.J. Wellens. 1997. Out-of-hospital cardiac arrest in the 1990s: a population-based study in the Maastricht area on incidence, characteristics and survival. Journal of the American College of Cardiology 30(6): 1500–1505.PubMedCrossRef
2.
Geppert, A., G. Zorn, G.D. Karth, M. Haumer, M. Gwechenberger, J. Koller-Strametz, G. Heinz, K. Huber, and P. Siostrzonek. 2000. Soluble selectins and the systemic inflammatory response syndrome after successful cardiopulmonary resuscitation. Critical Care Medicine 28(7): 2360–2365.PubMedCrossRef
3.
Adrie, C., M. Adib-Conquy, I. Laurent, M. Monchi, C. Vinsonneau, C. Fitting, F. Fraisse, A.T. Dinh-Xuan, P. Carli, C. Spaulding, J.F. Dhainaut, and J.M. Cavaillon. 2002. Successful cardiopulmonary resuscitation after cardiac arrest as a “sepsis-like” syndrome. Circulation 106(5): 562–568.PubMedCrossRef
4.
Nolan, J.P., R.W. Neumar, C. Adrie, M. Aibiki, R.A. Berg, B.W. Bbttiger, C. Callaway, R.S. Clark, R.G. Geocadin, E.C. Jauch, K.B. Kern, I. Laurent, W.T. Longstreth, R.M. Merchant, P. Morley, L.J. Morrison, V. Nadkarni, M.A. Peberdy, E.P. Rivers, A. Rodriguez-Nunez, F.W. Sellke, C. Spaulding, K. Sunde, and H.T. Vanden. 2010. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication: a scientific statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke (Part II). International Emergency Nursing 18(1): 8–28.PubMedCrossRef
5.
Cook-Mills, J.M., and T.L. Deem. 2005. Active participation of endothelial cells in inflammation. Journal of Leukocyte Biology 77(4): 487–495.PubMedCrossRef
6.
Boyle, E.J., T.J. Canty, E.N. Morgan, W. Yun, T.H. Pohlman, and E.D. Verrier. 1999. Treating myocardial ischemia–reperfusion injury by targeting endothelial cell transcription. The Annals of Thoracic Surgery 68(5): 1949–1953.PubMedCrossRef
7.
Serhan, C.N., and E. Oliw. 2001. Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. Journal Clinical Investigations 107(12): 1481–1489.CrossRef
8.
Ye, X.H., Y. Wu, P.P. Guo, J. Wang, S.Y. Yuan, Y. Shang, and S.L. Yao. 2010. Lipoxin A4 analogue protects brain and reduces inflammation in a rat model of focal cerebral ischemia reperfusion. Brain Research 1323: 174–183.PubMedCrossRef
9.
Leonard, M.O., K. Hannan, M.J. Burne, D.W. Lappin, P. Doran, P. Coleman, C. Stenson, C.T. Taylor, F. Daniels, C. Godson, N.A. Petasis, H. Rabb, and H.R. Brady. 2002. 15-Epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure. Journal of the American Society of Nephrology 13(6): 1657–1662.PubMedCrossRef
10.
Peskar, B.M., K. Ehrlich, R. Schuligoi, and B.A. Peskar. 2009. Role of lipoxygenases and the lipoxin A(4)/annexin 1 receptor in ischemia–reperfusion-induced gastric mucosal damage in rats. Pharmacology 84(5): 294–299.PubMedCrossRef
11.
Serhan, C.N., A. Jain, S. Marleau, C. Clish, A. Kantarci, B. Behbehani, S.P. Colgan, G.L. Stahl, A. Merched, N.A. Petasis, L. Chan, and T.E. Van Dyke. 2003. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. Journal of Immunology 171(12): 6856–6865.
12.
Takano, T., C.B. Clish, K. Gronert, N. Petasis, and C.N. Serhan. 1998. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. Journal of Clinical Investigation 101(4): 819–826.PubMedCrossRef
13.
Takano, T., S. Fiore, J.F. Maddox, H.R. Brady, N.A. Petasis, and C.N. Serhan. 1997. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. The Journal of Experimental Medicine 185(9): 1693–1704.PubMedCrossRef
14.
Devchand, P.R., M. Arita, S. Hong, G. Bannenberg, R.L. Moussignac, K. Gronert, and C.N. Serhan. 2003. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. The FASEB Journal 17(6): 652–659.CrossRef
15.
Birnbaum, Y., Y. Ye, Y. Lin, S.Y. Freeberg, S.P. Nishi, J.D. Martinez, M.H. Huang, B.F. Uretsky, and J.R. Perez-Polo. 2006. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 114(9): 929–935.PubMedCrossRef
16.
Chen, M.H., L. Xie, T.W. Liu, F.Q. Song, T. He, Z.Y. Zeng, and S.R. Mo. 2007. Epinephrine, but not vasopressin, improves survival rates in an adult rabbit model of asphyxia cardiac arrest. The American Journal of Emergency Medicine 25(5): 509–514.PubMedCrossRef
17.
Hammel, J.M., C.A. Caldarone, T.L. Van Natta, L.X. Wang, K.F. Welke, W. Li, S. Niles, E. Barner, T.D. Scholz, D.M. Behrendt, and J.L. Segar. 2003. Myocardial apoptosis after cardioplegic arrest in the neonatal lamb. The Journal of Thoracic and Cardiovascular Surgery 125(6): 1268–1275.PubMedCrossRef
18.
Borutaite, V., and G.C. Brown. 2003. Mitochondria in apoptosis of ischemic heart. FEBS Letters 541(1–3): 1–5.PubMedCrossRef
19.
Song, F., Y. Shan, F. Cappello, F. Rappa, G. Ristagno, T. Yu, V.G. Li, S. Sun, M.H. Weil, and W. Tang. 2010. Apoptosis is not involved in the mechanism of myocardial dysfunction after resuscitation in a rat model of cardiac arrest and cardiopulmonary resuscitation. Critical Care Medicine 38(5): 1329–1334.PubMed
20.
Ryan, A., and C. Godson. 2010. Lipoxins: regulators of resolution. Current Opinion in Pharmacology 10(2): 166–172.PubMedCrossRef
21.
Wu, J., A. Wang, Z. Min, Y. Xiong, Q. Yan, J. Zhang, J. Xu, and S. Zhang. 2011. Lipoxin A4 inhibits the production of proinflammatory cytokines induced by beta-amyloid in vitro and in vivo. Biochemistry Biophysics Research Communication 408(3): 382–387.CrossRef
22.
Baker, N., S.J. O’Meara, M. Scannell, P. Maderna, and C. Godson. 2009. Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells. Journal of Immunology 182(6): 3819–3826.CrossRef
23.
Turer, A.T., and J.A. Hill. 2010. Pathogenesis of myocardial ischemia–reperfusion injury and rationale for therapy. The American Journal of Cardiology 106(3): 360–368.PubMedCrossRef
24.
Laurent, I., M. Monchi, J.D. Chiche, L.M. Joly, C. Spaulding, B. Bourgeois, A. Cariou, A. Rozenberg, P. Carli, S. Weber, and J.F. Dhainaut. 2002. Reversible myocardial dysfunction in survivors of out-of-hospital cardiac arrest. Journal of the American College of Cardiology 40(12): 2110–2116.PubMedCrossRef
25.
Ruiz-Bailen, M., D.H.E. Aguayo, S. Ruiz-Navarro, M.A. Diaz-Castellanos, L. Rucabado-Aguilar, F.J. Gomez-Jimenez, S. Martinez-Escobar, R.M. Moreno, and J. Fierro-Roson. 2005. Reversible myocardial dysfunction after cardiopulmonary resuscitation. Resuscitation 66(2): 175–181.PubMedCrossRef
26.
Weerateerangkul, P., S. Chattipakorn, and N. Chattipakorn. 2011. Roles of the nitric oxide signaling pathway in cardiac ischemic preconditioning against myocardial ischemia–reperfusion injury. Medical Science Monitor 17(2): A44–A52.CrossRef
27.
Vinten-Johansen, J., R. Jiang, J.G. Reeves, J. Mykytenko, J. Deneve, and L.J. Jobe. 2007. Inflammation, proinflammatory mediators and myocardial ischemia–reperfusion Injury. Hematology/Oncology Clinics of North America 21(1): 123–145.PubMedCrossRef
28.
Moro, C., M.G. Jouan, A. Rakotovao, M.C. Toufektsian, O. Ormezzano, N. Nagy, A. Tosaki, J. de Leiris, and F. Boucher. 2007. Delayed expression of cytokines after reperfused myocardial infarction: possible trigger for cardiac dysfunction and ventricular remodeling. America Journal Physiology Heart Circulatory Physiology 293(5): H3014–H3019.CrossRef
29.
Baker, R.G., M.S. Hayden, and S. Ghosh. 2011. NF-kappaB, inflammation, and metabolic disease. Cell Metabolism 13(1): 11–22.PubMedCrossRef
30.
Souza, D.G., C.T. Fagundes, F.A. Amaral, D. Cisalpino, L.P. Sousa, A.T. Vieira, V. Pinho, J.R. Nicoli, L.Q. Vieira, I.M. Fierro, and M.M. Teixeira. 2007. The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice. Journal of Immunology 179(12): 8533–8543.
31.
Jozsef, L., C. Zouki, N.A. Petasis, C.N. Serhan, and J.G. Filep. 2002. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Processing Nationale Academie Science U S A 99(20): 13266–13271.CrossRef
32.
Yang, J., H. Jiang, J. Yang, J.W. Ding, L.H. Chen, S. Li, and X.D. Zhang. 2009. Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway. Molecular and Cellular Biochemistry 330(1–2): 39–46.PubMedCrossRef
Metadata
Title
Effect of Lipoxin A4 on Myocardial Ischemia Reperfusion Injury Following Cardiac Arrest in a Rabbit Model
Publication date
01-04-2013
Published in
Inflammation / Issue 2/2013
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-012-9567-x

Other articles of this Issue 2/2013

Inflammation 2/2013 Go to the issue

OriginalPaper

Evaluation of CHI3L-1 and CHIT-1 Expression in Differentiated and Polarized Macrophages

OriginalPaper

A High-Fat Diet Increases IL-1, IL-6, and TNF-α Production by Increasing NF-κB and Attenuating PPAR-γ Expression in Bone Marrow Mesenchymal Stem Cells

OriginalPaper

An Extragranular Compartment of Blood Eosinophils Contains Eosinophil Protein X/Eosinophil-Derived Neurotoxin (EPX/EDN)

OriginalPaper

Phlorofucofuroeckol A Suppresses Expression of Inducible Nitric Oxide Synthase, Cyclooxygenase-2, and Pro-inflammatory Cytokines via Inhibition of Nuclear Factor-κB, c-Jun NH2-Terminal Kinases, and Akt in Microglial Cells

OriginalPaper

Mast Cells in Human Stenotic Aortic Valves Are Associated with the Severity of Stenosis

OriginalPaper

Inhibitory Mechanism of 10-Hydroxy-trans-2-decenoic Acid (Royal Jelly Acid) Against Lipopolysaccharide- and Interferon-β-Induced Nitric Oxide Production

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits